In patients with advanced, refractory cancer, autologous NY-ESO-1 TCR–engineered T cells in patients after CRISPR–Cas9 editing of the TRAC, TRBC, and PDCD1 loci were infused with lasting persistence for 9 months. The gene discussed is PDCD1; the disease is cancer.